FDA's "critical path" will modernise device evaluations
This article was originally published in Clinica
Executive Summary
Imaging of the peripheral vasculature, ablative therapies and cataractous crystalline lenses are some of the device-related issues that are likely to be addressed as part of the FDA's new "critical path" initiative, according to Larry Kessler, director of science and technology at the FDA's Center for Devices and Radiological Health.